Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 28.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,068 shares of the medical technology company’s stock after acquiring an additional 7,825 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Alphatec were worth $195,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ATEC. BNP Paribas Financial Markets increased its position in shares of Alphatec by 73.7% during the third quarter. BNP Paribas Financial Markets now owns 21,603 shares of the medical technology company’s stock worth $120,000 after purchasing an additional 9,165 shares in the last quarter. Algert Global LLC acquired a new position in Alphatec during the 3rd quarter valued at about $1,452,000. Charles Schwab Investment Management Inc. raised its stake in Alphatec by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company’s stock valued at $4,577,000 after buying an additional 15,577 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Alphatec in the third quarter worth about $189,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after acquiring an additional 297,850 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ATEC shares. Barclays lifted their target price on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Finally, Lake Street Capital cut their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $17.11.

Alphatec Stock Up 0.4 %

Shares of ATEC opened at $9.63 on Monday. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -7.52 and a beta of 1.38. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34. The stock’s 50-day moving average price is $7.55 and its 200-day moving average price is $8.14. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.